Showing results (141-150 of 553) with videos related to
Sort By:
Pageof 56
Drugs in Context|June 17, 2025
Conservative management of paediatric dacryocystitis: a collection of clinical experiences highlighting effectiveness and parental satisfactionStefano Russo, Antonio Valentino Giugliano, Ida Cesarano, et al.Drugs in Context|June 17, 2025
Platinum-induced ototoxicity and hearing impairment in children and adolescentsAlberto Romano, Giorgio Attinà, Palma Maurizi, et al.Drugs in Context|May 19, 2025
Upadacitinib for the treatment of radiographic axial spondyloarthritis - case series and review of the literatureGiuseppe Lopalco, Arianna D'Antonio, Maria Sole Chimenti, et al.Drugs in Context|August 20, 2025
Properties and potentialities of hyaluronic acid and eXcellent Tridimensional Reticulation as a filling agent: a reviewVincent Wong, Martina ManniDrugs in Context|February 16, 2026
Ustekinumab-associated morphoea: systematic review of the literature and a real-world caseMarco Sousa, José Miguel Alvarenga, Ana Maria Lé, et al.Drugs in Context|February 28, 2018
Treatment with combined dabrafenib and trametinib in BRAFV600E-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessationSonia Brugnara, Mariacristina Sicher, Elena Maria Bonandini, et al.Drugs in Context|November 29, 2018
The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibitionMuhammad Saad, Umut Gomceli, Pranav Ravi, et al.Drugs in Context|November 29, 2018
Impact of adalimumab on clinical outcomes, healthcare resource utilization, and sick leave in patients with ankylosing spondylitis: an observational study from five Central and Eastern European countriesDaniela Opris-Belinski, Shandor F Erdes, Simeon Grazio, et al.Drugs in Context|December 22, 2018
Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugsPedro Luis Gonzalez, Urania Rappo, Karthik Akinapelli, et al.Drugs in Context|January 11, 2019
Anti-angiogenesis therapy, synthetic lethality, and checkpoint inhibition in ovarian cancer: state of the science and novel combinationsMarisa C Liu, Krishnansu S TewariPageof 56